Patents by Inventor Andre Habel
Andre Habel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9655961Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.Type: GrantFiled: September 26, 2013Date of Patent: May 23, 2017Assignees: INSTITUT PASTEUR, THEMIS BIOSCIENCE GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel
-
Publication number: 20150238592Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.Type: ApplicationFiled: September 26, 2013Publication date: August 27, 2015Applicant: INSTITUT PASTEURInventors: Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel
-
Publication number: 20150010595Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: June 11, 2014Publication date: January 8, 2015Applicant: Valneva Austria GmbHInventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 8784837Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: GrantFiled: April 13, 2010Date of Patent: July 22, 2014Assignee: Valneva Austria GmbHInventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Publication number: 20100297170Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: April 13, 2010Publication date: November 25, 2010Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 7704514Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZXZN-XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: GrantFiled: March 22, 2004Date of Patent: April 27, 2010Assignee: Intercell AGInventors: Michael Buschle, André Habel, Jörge Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 7528223Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.Type: GrantFiled: July 24, 2003Date of Patent: May 5, 2009Assignee: Intercell AGInventors: Frank Mattner, Walter Schmidt, Andre Habel
-
Publication number: 20090081246Abstract: Described are methods for isolating Hepatitis C Virus peptides (HPs) that have a binding capacity to a MHC/HLA molecule or a complex comprising the HCV-peptide and the MHC/HLA molecule. In one aspect, these methods include providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex. Also described are immunogenic compositions that stimulate a specific T cell response to hepatitis C virus when administered to a subject in an effective amount.Type: ApplicationFiled: April 30, 2008Publication date: March 26, 2009Inventors: Michael Buschle, Andre Habel, Christoph Klade, Frank Mattner, Oleksandr Otava, Oresta Vytvytska, Wolfgang Zauner, Sandra Zinke, Helen Kirlappos
-
Patent number: 7431928Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: GrantFiled: January 26, 2006Date of Patent: October 7, 2008Assignees: Institut Pasteur, Institut National de la Sante et de la RechercheInventors: Sylvain Cardinaud, André Habel, Pierre Langlade-Demoyen, François Lemonnier
-
Patent number: 7378234Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.Type: GrantFiled: August 27, 2003Date of Patent: May 27, 2008Assignee: Intercell AGInventors: Michael Buschle, Andre Habel, Christoph Klade, Frank Mattner, Alexander Otava, Oresta Vytvytska, Wolfgang Zauner, Sandra Zinke, Helen Kirlappos
-
Publication number: 20070134262Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.Type: ApplicationFiled: July 24, 2003Publication date: June 14, 2007Applicant: Intercell AGInventors: Frank Mattner, Walter Schmidt, Andre Habel
-
Publication number: 20060263386Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZXZN-XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: March 22, 2004Publication date: November 23, 2006Applicant: Intercell AGInventors: Michael Buschle, Andre Habel, Jorg Fritz, Karin Prinz, Karen Lingnau
-
Publication number: 20060216691Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.Type: ApplicationFiled: August 27, 2003Publication date: September 28, 2006Applicant: Intercell AGInventors: Michael Buschle, Andre Habel, Christoph Klade, Frank Mattner, Oleksandr Otava, Oresta Vytvytska, Wolfgang Zauner, Sandra Zinke, Helen Kirlappos
-
Publication number: 20060115488Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: ApplicationFiled: January 26, 2006Publication date: June 1, 2006Inventors: Sylvain Cardinaud, Andre Habel, Pierre Langlade-Demoyen, Francois Lemonnier
-
Patent number: 7022325Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: GrantFiled: September 27, 2002Date of Patent: April 4, 2006Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche MedicaleInventors: Sylvain Cardinaud, André Habel, Pierre Langlade-Demoyen, François Lemonnier
-
Publication number: 20050163796Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs: 1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: ApplicationFiled: September 27, 2002Publication date: July 28, 2005Inventors: Sylvain Cardinaud, Andre Habel, Pierre Langlade-Demoyen, Francois Lemonnier